MedTrace Logo

A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus

NCT00282971 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2019-04-02

Study results available
· View outcomes & findings →

Summary

To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Inhaled Insulin (Exubera)

Addition of inhaled insulin to pre-existing oral diabetes therapy.

OTHER

Standard of Care

Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-06
Primary Completion
2008-02-19
Completion
2008-02-19
FDA Drug
Yes

Countries

  • Canada
  • France
  • Greece
  • Portugal
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00282971 on ClinicalTrials.gov